Clinical Study | Office of Clinical Research

Nrg-Gy004- A Phase III Study Comparing Single-Agent Olaparib Or The Combination Of Cediranib And Olaparib To Standard Platinum-Based Chemotherapy In Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer

Posted Date: Jun 10, 2019

Investigator: Thomas Herzog
Specialties: Cancer, Oncology, Ovarian Cancer
Type of Study: Drug

The goal of this study is to assess the efficacy of either single agent olaparib or the combination of cediranib and olaparib, as measured by PFS, as compared to standard platinum-based chemotherapy in the setting of recurrent platinum-sensitive ovarian, primary peritoneal or fallopian tube cancer.

Criteria:

To Be Eligible: Patient Must Be 18 Years Of Age Or Older, Must Have Adequate Thyroid Function, Must Be Able To Swallow And Retain Oral Medications, Must Have Platinum-Sensitive Recurrent High Grade Serous Or Endometrioid Ovarian, Primary Peritoneal, Or Fa

Keywords:

Ovarian Cancer, Fallopian Tube, Peritoneal

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List